Twist Bioscience Corporation (TWST)

NASDAQ: TWST · Real-Time Price · USD
25.31
-0.30 (-1.17%)
At close: Sep 12, 2025, 4:00 PM EDT
25.42
+0.11 (0.43%)
After-hours: Sep 12, 2025, 6:52 PM EDT
-1.17%
Market Cap1.53B
Revenue (ttm)362.27M
Net Income (ttm)-85.19M
Shares Out 60.36M
EPS (ttm)-1.44
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,503,418
Open25.35
Previous Close25.61
Day's Range24.91 - 25.56
52-Week Range24.07 - 55.33
Beta2.31
AnalystsBuy
Price Target50.67 (+100.2%)
Earnings DateAug 4, 2025

About TWST

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and ... [Read more]

Sector Healthcare
IPO Date Oct 31, 2018
Employees 923
Stock Exchange NASDAQ
Ticker Symbol TWST
Full Company Profile

Financial Performance

In 2024, Twist Bioscience's revenue was $312.97 million, an increase of 27.69% compared to the previous year's $245.11 million. Losses were -$208.73 million, 2.01% more than in 2023.

Financial Statements

Analyst Summary

According to 9 analysts, the average rating for TWST stock is "Buy." The 12-month stock price target is $50.67, which is an increase of 100.20% from the latest price.

Price Target
$50.67
(100.20% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Twist Bioscience to Present at Baird 2025 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder...

10 days ago - Business Wire

Twist Bioscience Collaborates with Synthetic Design Lab

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has collaborated with next generation the...

11 days ago - Business Wire

mRNA Biotechs - Long-Term Value Risks Abound

mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...

16 days ago - Seeking Alpha

Twist Bioscience Launches Oncology DNA CGP Panel to Advance Precision Medicine with Customizable, Platform-Agnostic NGS Solution

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity, in the life sciences segment of the health care sector, today launche...

25 days ago - Business Wire

Twist Bioscience: Headwinds Are Mounting

Twist Bioscience's growth continues to moderate, in part due to macro headwinds. While Twist's focus on transitioning to profitability in the near-term has significantly reduced cash burn, it has also...

4 weeks ago - Seeking Alpha

Twist Bioscience Appoints Trynka Shineman Blake to Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth equity, today announced the appointment of Trynka Shineman Blake to its board of direct...

5 weeks ago - Business Wire

Twist Bioscience Turns The Tide: Q3 Sales Jump, Beats Earnings

What if a biotech company could flip its financial narrative from loss to profit in just a year? Twist Bioscience Corporation TWST has done just that, reporting a surprising third-quarter income that ...

5 weeks ago - Benzinga

Twist Bioscience Corporation (TWST) Q3 2025 Earnings Call Transcript

Twist Bioscience Corporation (NASDAQ:TWST) Q3 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Adam Laponis - Chief Financial Officer Angela Bitting - Chief Corporate Resp...

5 weeks ago - Seeking Alpha

Twist Bioscience Announces Fiscal 2025 Third Quarter Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth equity, today announced financial results and business highlights for the third quarter...

5 weeks ago - Business Wire

Twist Bioscience Expands In Vivo Antibody Discovery Services with Launch of Humanized Transgenic Mouse Model

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today ...

6 weeks ago - Business Wire

Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a core mid-cap growth and val...

7 weeks ago - Business Wire

Twist Bioscience: Still Not There Yet

Twist Bioscience continues to grow revenue at a healthy pace, posting 23% year-over-year sales growth and beating EPS expectations in its most recent quarter. The company holds $255 million in cash an...

2 months ago - Seeking Alpha

Twist Bioscience to Report Fiscal 2025 Third Quarter Financial Results on Monday, August 4, 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today ...

2 months ago - Business Wire

Twist Bioscience Expands Express Delivery Turnaround Time to All Gene Fragments Regardless of Format

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today ...

2 months ago - Business Wire

Twist Bioscience and Element Biosciences Expand Collaboration to Transform Next Generation Sequencing Workflows with Co-Developed End-to-End Solutions

SOUTH SAN FRANCISCO, Calif. & SAN DIEGO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care se...

4 months ago - Business Wire

Twist Bioscience to Present at William Blair 45th Annual Growth Stock Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today ...

4 months ago - Business Wire

Twist Bioscience and Ginkgo Bioworks Revise Collaboration

SOUTH SAN FRANCISCO, Calif. & BOSTON--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care secto...

Other symbols: DNA
4 months ago - Business Wire

Twist Bioscience: Expansion Efforts Continue To Face Challenges

Twist Bioscience reported solid results in Q2, but management's downbeat tone on the earnings call suggest there are challenges ahead. Twist has also spun-out its data storage business, which will hel...

4 months ago - Seeking Alpha

Twist Bioscience Corporation (TWST) Q2 2025 Earnings Call Transcript

Twist Bioscience Corporation (NASDAQ:TWST) Q2 2025 Earnings Conference Call April 5, 2025 8:00 AM ET Company Participants Angela Bitting - Senior Vice President of Corporate Affairs Emily Leproust - ...

4 months ago - Seeking Alpha

Twist Bioscience Announces Fiscal 2025 Second Quarter Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today ...

4 months ago - Business Wire

Twist Bioscience Spins Out DNA Data Storage as Independent Company

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today ...

4 months ago - Business Wire

Twist Bioscience Q2 Earnings Preview: Innovative Products, Not Enough Buyers

Twist Bioscience has shown revenue growth from $54.4m in 2019 to potentially >$300m in 2024, but continues to post losses. Despite a diverse customer base and innovative synthetic DNA technology, Twis...

4 months ago - Seeking Alpha

Twist Bioscience Expands Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Expands Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System.

5 months ago - Business Wire

Twist Bioscience and Curio Genomics Collaborate to Accelerate and Streamline NGS Adoption in Agrigenomics

SOUTH SAN FRANCISCO, Calif. & ANN ARBOR, Mich.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health ...

5 months ago - Business Wire

Twist Bioscience Offers Clonal Genes for Global Academic Researchers at Express Speed for No Extra Cost

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today ...

6 months ago - Business Wire